Topic Listing for Accentia Biopharmaceuticals

Abpi Acquisition Inc Delaware Corporation Other Accelerated Approval
Accelerated Approval Subpart 21cfr 601 Biological Products Serious Accent Inc Complaint
Accentia Accentia Biopharmaceuticals
Accentia Biopharmaceuticals Announces Financial Results 2005 Accentia Biopharmaceuticals Announces Follow-up Data Phase Clinical Trial
Accentia Biopharmaceuticals Announces Pending Delisting Nasdaq Accentia Biopharmaceuticals Inc
Accentia Biopharmaceuticals Inc Corporate Contact Accentia Biopharmaceuticals Inc Corporate Contacts
Accentia Biopharmaceuticals Inc Enters Definitive Agreement Convertible Debenture Accentia Biopharmaceuticals Inc Launches Crsfungal Profile Diagnostic Test
Accentia Biopharmaceuticals Raise 82m Equity Financing Accentia Biopharmaceuticals Receives Nasdaq Compliance Notice
Accentia Biopharmaceuticals Receives Nasdaq Notice Accentia Pioneered Nmtcs Support Biotechnology Opportunities 2006
Accentia Pledge Agreement Accentia Transfers Listing Nasdaq Capital Market
Account Name Biovest Maintained North Fork Bank Restricted Account Number 270-405-7542
Accounting Nmtc Financing Arrangement Variable Interest Entities Accounting Procedures Control Funds Assets
Accounts Payable Reconciliation Post Petition Unsecured Debt Only Accounts Receivable Concentrations Credit Risk Customer Vendor
Accounts Receivable Reconciliation Accounts Receivable Stockholder
Accuracy Retention Disposal Records Acheron Hereby Release Accentia Teamm Officers Employees Directors
Acquire Other Complementary Technologies Companies Financial Performance Suffer Acquisition
Acquisitions Dispositions Acsimile Ail
Additional Information Autovaxid Contact Address Notice
Address Notices Address Notices Selling Securityholder
Address Notices Selling Stockholder Address Principal Executive Offices Zip Code
Adjustments Awards Administration Participants
Advance Key Strategies Sinunase Revimmune Advantages Autovaxid Over Conventional Cell Culture Methods
Advertising Expense Agent
Aggregate Option Exercises Last Year-end Values Agreed Accepted Date Hereof
Agreement Agreement Consent
Agreement License Transfer Assets Agreement Shall Governed Interpreted Rights Obligations Parties Determined
Agreements Biovest Allernase
Allocation Pledged Shares Also Reports Nasdaq Compliance Plan
Amendatory Supplemental Letter Agreement Amended Restated Secured Non-convertible Revolving
Amended Restated Security Agreement Amended Restated Stock Pledge Agreement
Amendment Amendment Financial Obligation
Amendment Laurus Amendment Laurus Loan
Amendment Laurus Loan Loss Extinguishment Debt Amendment License Agreement
Amendment Overadvance Side Letter Dated Amendment Sublicense Agreement
Amendments Amendments Articles Incorporation Bylaws
Amendments Other Agreements Amendments Ppd Agreements
American Stock Transfer Trust Inc Amortizing Term
Analytica Litigation Anda 505 Applicant Challenges Patents Generic Exclusivity
Annex Announced Analysis Unblinded Primary Endpoint Datas Initial Phase
Announced Analysis Unblinded Primary Endpoint Datas Phase Clinical Annual Meeting Shareholders
Anti-harassment Policy Anticipate Need Substantial Additional Funding Future Unable Raise
Antifungal Shall Mean Composition Other Amphotericin-b Option Aplastic Anemia
Applicable Laws Applications
Appointment Deliveries Escrow Agent Appropriate Nondisclosure Agreements
Approval 2008 Approved Pharmaceutical Available
Asset Purchase Agreement Asset Sale
Assignment Form Assignment Sale Proceeds
Assumption Assumed Liabilities Attend Annual Meeting
Attend Meeting Attn Ceo
Audit Related Fees Authorized
Autoimmune Hemolytic Anemia Automatic Director Award
Autovaxid Brings Sophisticated Hollow Fiber Technology Within Reach Autovaxid Ideal Laboratories Need Produce Gram Amounts Cell
Autovaxid Inc Autovaxid Products Services
Autovaxid Self-contained Automated Cell Growth Instrument Available Information
Award Agreement Awards Participants Outside United States
Background Background Chronic Sinusitis
Background Chronic Sinusitis Sinunase Background Revimmune
Bank Subordination Agreement Based Responses 750 Ent Specialists
Basis Presentation Been Denied Orphan Drug Exclusivity Biovaxid Competitors Obtain
Before Seek Regulatory Approval Sinunase Biovaxid Other Product Before Seek Regulatory Approval Sinunase Biovaxid Revimmune Other
Beneficial Ownership Reporting Compliance Beneficial Ownership Reporting Requirements
Binding Effect Biolender Purchase Agreement
Biologics Distribution Agreement Mckesson Biologics Production
Biopharmaceutical Products Biopharmaceutical Products Services
Biovaxid Biovaxid Fast-tracked Phase Study Description
Biovaxid Manufacturing Biovaxid Phase Clinical Trial Identifiable Safety Concerns
Biovaxid Summary Results End Study Biovaxid Treatment Non-hodgkins Lymphoma
Biovaxid Treatment Production Process Biovest Accelerated Conditional Approval Biovaxid
Biovest International Bvti Granted Following Registration Rights Biovest International Inc
Biovest International Inc Corporate Contact Biovest International Inc Corporate Contacts
Biovest Investment Agreement Biovest Litigation
Biovest Media Alert Baltimore Sun Reports Patient Worldwide Biovest Need Substantial Additional Funding Sources Other Future
Biovest Vwr Enter Marketing Distribution Agreement Autovaxid Blockbuster Potential
Board Committees Board Directors
Board Directors Unanimously Recommends Vote Approval Each Proposals Board Meetings Independence
Borrower Acknowledgement Breach Certain Representations Warranties Covenants Instruments Governing 2006
Broker-dealer Status Business Governments Officials
Business Organization Business Segments
Business Strategy Bvti Wholly-owned Subsidiaries
Call Right Cancer Cells Indolent Otherwise Normally Fatal
Cannot Certain Receive Fast-track Status Fda Sinunase Cannot Predict Impact Fast-track Status Regulatory Approval Process
Capital Adjustments Capital Raised Through Equity Issuances
Capital Terms Used Herein Not Otherwise Defined Shall Carlos Santos Lee Stern Laura Katz Thelma Watson
Cash Equivalents Cash Flows 2003
Cash Flows 2004 Cash Flows 2005
Cash Flows 2006 Cash Flows 2007
Cash Flows 2008 Cash Resources
Causes Treatment Causes Treatment Crs
Ceo Conference Call Webcast Scheduled 500 Edt Certain Relationships Related Transactions
Certificates Shares Transfer Certification
Change Vote After Return Proxy Card Changes Critical Accounting Policies Regarding Embedded Derivatives Resulting
Check Register Operating Account Check Register Payroll Account
Check Register Tax Account Check Register-operating Account
Check Register-payroll Account Check Register-tax Account
Chief Executive Officer Senior Financial Chronic Sinusitis
Class Director Terms Expire 2007 Annual Meeting Shareholders Class Directors Term Expire 2007 Annual Meeting Shareholders
Class Directors Term Expire 2010 Annual Meeting Shareholders Class Directors Term Expire 2011 Annual Meeting Shareholders
Class Directors Terms Expire 2008 Annual Meeting Shareholders Class Directors Terms Expire 2009 Annual Meeting Shareholders
Clinical Studies Amphotericin Therapy Clinical Studies Ultra-high Intensity Intravenous Cyclophosphamide
Clinical Trials Sinunase Biovaxid Demonstrated Certain Side Effects Clinical Trials Sinunase Biovaxid Produce Negative Inconclusive Results
Clinical Trials Sinunase Biovaxid Revimmune Produce Negative Inconclusive Closing
Closing Comments Closing Statement
Code Business Conduct Ethics Collateral Assignment
Commercialization Product Candidates Not Profitable Commitments Contingencies
Common Stock Communications Board Directors
Comparison Issuer Proceeds Potential Investor Profit Comparison Registered Shares Outstanding
Comparison Total Return Among Accentia Biopharmaceuticals Inc Russell Compassionate-use Program Soon Launch Europe
Compensation Committee Interlocks Insider Participation Compensation Discussion Analysis
Compensation Executive Officers Compensation Philosophy
Competition Competitive Information
Competitors Develop Products Less Expensive Safer Effective Diminish Completion Acquisition Disposition Assets
Compliance Concentrations Credit Risk Customer Vendor
Concerning Escrow Agent Condensed Consolidated Balance Sheets
Conditional Approval Subpart 21cfr 601 Accelerated Biological Products Conditions Lending
Conditions Obligations Buyer Conditions Obligations Seller
Confidentiality Confirmation Insurance
Consent Agreement Reaffirmation Release Consent Spouse Guaranty
Consolidated Balance Sheets Consolidated Results Operations
Consolidation Policy Construction
Contact Contact Media Public Attorneys
Contact Members Board Contacts
Continue Operations Commercialize Drug Portfolio Contract Manufacturer
Contract Rate Contract Rate Amortization
Contract Rate Minimum Borrowing Contracts Loans Checks Deposits Special Corporate Acts
Contractual Obligations Off-balance Sheet Arrangements Controls Procedures
Conversion Accrued Dividends Preferred Stock Conversion Exchange Schedule
Conversion Rights Fixed Price Conversion Schedule
Convertible Amortizing Term Convertible Debentures 2006
Convertible Debentures 2007 Convertible Debentures 2008
Convertible Loan Agreement Convertible Preferred Stock Financing Dated 2008 Related Documents
Cooperative Research Development Agreement Corporate History Structure
Corporate Opportunities Conflicts Interest Cost Sales
Count Vote Counterpart Signature Page Convertible Loan Agreement
Counterparts Covenants Parties
Creation Direct Financial Obligation Off-balance Sheet Arrangement Creation Financial Obligation
Credit Facilities Valens Funds Critical Accounting Policies Estimates
Crsfungal Profile Laboratory Diagnostic Available Chronic Sinusitis Currently Depend Sole-source Supplier Klh Critical Raw Material
Currently Marketed Products Customer Relationships
Customers Customers Generate Large Portion Revenue Reduction Delay Cancellation
Customers Generates Large Portion Revenue Reduction Delay Cancellation Dated 2006
Dated 2007 Deadline Receipt Shareholder Proposals
Debentures Financing Dated 2006 Debentures Financing Dated 2006 Related Documents
Debentures Financing Dated 2007 Debentures Financing Dated 2007 Related Documents
Debentures Warrants Debit Cards Not Issued Account
Debt Financing Declare Penalty Perjury Statement Accompanying Documents Reports True
Dedicated Autovaxid Manufacturing Facility Louis Operational 2007 Defaults
Deferred Finance Costs Deferred Offering Costs
Definitions Delaware Limited Liability
Delays Clinical Testing Result Increased Costs Delay Ability Delivery Proxy Materials Households
Demand Departure Directors Principal Officer Election Appointment Officers
Departure Directors Principal Officers Election Appointment Dependent Third-party Development Partners Regulatory Approval Some Products
Derivative Instruments Derivative Liabilities
Description Description Business Summary Significant Accounting Policies
Description Collateral Description Private Placement
Development Commercialization Capabilities Development Patient-specific Therapeutic Vaccine Nhl
Development Patient-specific Vaccine Nhl Development Plan
Development Status Director Compensation
Directors Executive Officers Disposition
Dispositions Dissolution
Distribution Agreement Distribution Agreement Arius
Dividends Dmc Recommends Biovaxid Trial Halted Early
Dollar Value Underlying Securities Potential Profits Conversion Domestic Foreign Operations
Driving Shareholder Value Drug Alcohol Abuse
Due Employees Ecurity Greement
Effect Failure Obtain Shareholder Approval Proposal Effect Shareholder Approval Proposal
Effective Amendment Date Revolving Hereby Amended Restated Form Efficacy
Election Directors Election Exercise
Eliminate Autoimmunity Restore Lost Function Emezine
Employee Employee Benefit Plans
Employee Stock Options Employees
Employment Agreements Employment Agreements Executives
Entitled Vote Entry Amendment Material Definitive Agreement
Entry Material Definitive Agreement Environmental
Equal Opportunity Equity Compensation Plan Information
Equity Compensation Plans Equity Incentive Plan
Est Estimates
Events Default Events Default Related Provisions
Evolving Regulation Corporate Governance Public Disclosure Result Additional Exact Name Registrant Specified Charter
Example Calculation Issuance Additional Stock Except Product Deletions Set Forth Hereof Distribution Agreement
Except Set Forth Below Undersigned Not Beneficial Registered Exchange Act 1934
Exchangeable Convertible Debenture Financing Exclusion Warranty
Executed Holder Order Exercise Warrant Execution Copy
Execution Version Executive Compensation
Executive Officers Exercise Notice
Exhibits Existence Minority Stockholders Biovest Subsidiary Creates Potential Conflicts
Existing Priority Liens Expect Expand Development Clinical Research Marketing Capabilities Result
Expected Expedite Regulatory Pathway Approvals Expenses Plan
Experience Difficulties Manufacturing Biovaxid Obtaining Approval Change Site Experience Manufacturing Biovaxid Other Immunotherapies Number Patients Cost
Extends Control Exclusive Worldwide Rights Prescription Antifungals Fail Comply Extensive Regulations Enforced Fda Emea Other
Fail Enter Maintain Successful Strategic Relationships Product Candidates Fail Obtain Fda Approval Sinunase Biovaxid Other Current
Fail Obtain Fda Approval Sinunase Biovaxid Revimmune Other Failure Attract Retain Skilled Personnel Impair Product Development
Failure Enroll Patients Clinical Trials Cause Delays Developing Fair Value Debt Instruments
Fair Value Determination Privately-held Equity Securities Fair Value Financial Instruments
Fast-track Review Fda
Fda Gain Clarification Non-approvable Letter Emezine Fda-approved Intranasal Antifungal Disease
Federal State Enforcement Authorities Characterize Portion Fees Payable Fees
Fifth Amendment Distribution Agreement Finality Determinations
Financial Instruments Financial Review
Financial Statements Exhibits Financial Statements Pro Forma Information Exhibits
Financial Statements Supplemental Data Financing Relationship Biovest
Find Difficult Prevent Compounding Pharmacies Preparing Compounded Formulations Findings Based Clinical Experience Median Follow-up Data Ongoing
Fixed Asset Report Fluctuations Operating Results
Following Disbursements Paid Cash Not Include Reported Petty Following Lapse Insurance Coverage Occurred
Food Drug Administration Foreign Currency Translation
Foreign Exchange Rates Foreign Regulation
Form 10-k Form 10-q
Form 8-k Form Assignment
Form Control Acknowledgment Form Subscription
Form Transferor Endorsement Former Name Address Changed Since Last Report
Formulation Agreement Forward-looking Statements
Free Fair Competition Fullest Extent Permitted Law Each Party Agreement Severally
Funding Requirements Funds Escrow Agreement
Furniture Equipment Leasehold Improvements Further Text Page Signature Follows
Future Maturities Future Sales Common Stock Lower Market Price
General General Matters
General Release Not Extend Claims Creditor Know Suspect General Standards Conduct
Goodwill Intangible Assets Governing Law
Governing Law Construction Governing Law Governed Federal Applicable Lender Extent Preempted
Government Regulation Government Relations
Governmental Investigations Grants Plan-based Awards
Guarantee Indemnifications Guarantors
Guaranty Handling Confidential Information Others
Hatch-waxman Act Held 2006
Held 2007 Held 2008
Hopkins Capital Group Llc Http Archneurama-assnorg Cgi Reprint 658noc80042v1pdf
Http Wwwbaltimoresuncom News Nation Bal-tesickle30mar3004193226story Human Immune System
Idis Limited Illustrative Purposes Only
Impairment Assets Impairment Charges
Impairment Goodwill Intangible Assets Impairment Long-lived Assets
Impairment Testing Inability Obtain Approval Supplemental Ind Sinunase Encochleated Form
Inability Obtain Regulatory Approval Manufacturing Facility Manufacture Commercial Income Taxes
Incurred Significant Costs Development Efforts Date Never Generate Indemnification
Indemnification Agreement Indemnification Exculpation
Indemnity Agreement Independent Clinical Study Previously Demonstrated 100 Responding Patients
Index Index Financial Statements
Indirect Subsidiaries Shall Mean Information
Initial Members Insert Wire Instructions
Instrument Production Insurance Coverage Reimbursement Status Newly Approved Products Uncertain
Intangible Assets Intellectual Property
Intellectual Property Rights Intellectual Property Security Agreement
Intends Seek Approval Internationally Intercreditor Agreement
Interest Rates Interest Vaccine Intellectual Property Biovest
Interests Directors Officers Interim Analysis Anti-cancer Vaccine Biovaxid Conducted
Interpretation Intranasal Application Amphotericin
Introduction Inventories
Inventory Aging Inventory Fixed Assets Report
Inventory Mckesson Cardinal Amerisource 2006 Inventory Report
Investment Accounts Investment Representation Statement
Investor Acknowledgement Joinder Agreement
Jun-08 Jurisdiction
Jurisdiction Borrower Agrees Bankruptcy Court Shall Exclusive Hear Largely Dependent Success Most Significant Product Candidates Sinunase
Late Charge Payment Borrower Charged 5000 Regularly Scheduled Launch Calendar Through
Laurus Master Fund Ltd Laurus Master Fund Ltd Secured Revolving Term Convertible
Laurus Master Funds Ltd Legal Proceedings
Lenders Counterpart Signature Page Convertible Loan Agreement Lenders Counterpart Signature Page Qlici Loan Agreement
Letter Understanding Between Accentia Biopharmaceuticals Inc Respirics Level Indebtedness Reduces Financial Flexibility Impede Ability Operate
License License Grant
Licensing Distribution Agreement Limitation Incorporation Reference
Limitation Liability Limited Experience Attempting Comply Public Obligations Including 404
Limited Operating History Financial Results Uncertain Lines Credit
Liquidity Capital Resources Liquidity Managements Plans
List Exhibits List Indebtedness 2006
List Indebtedness 2007 List Schedules
Listing Maintenance Requirements Litigation
Loan Notice Loans Affiliates Related Parties
Loans Payments Lobbying
Long-term Debt Loss Extinguishment Debt
Loss Per Common Share Lymphoma Appears Offer Hope Cure Otherwise Fatal Cancer
Maker Acknowledges Read Understands Agrees Terms Conditions Receipt Management
Manufacture Biovaxid Manufacturing
Market Not Receptive Products Introduction Market Opportunity
Market Registrants Common Equity Related Stockholder Matters Issuer Market Registrants Common Stock
Master Service Agreement Matters Relating Biovest
Mckesson Corp Medical Device Regulation
Medical Device Veteran Board Directors Member
Memorandum Understanding Merger Consolidation Dissolution
Method Exercise Mikart Inc Letterhead
Miscellaneous Miscellaneous Provisions
Mold Cause Problems Monthly Accounts Payable Secured Payments Report
Monthly Accounts Receivable Reconciliation Aging Monthly Summary Bank Activity Operating Account
Monthly Summary Bank Activity Payroll Account Monthly Summary Bank Activity Tax Account
Monthly Summary Bank Activity-operating Account Monthly Summary Bank Activity-tax Account
Monthly Tax Report Multiple Sclerosis
Mutual Termination Agreement Myasthenia Gravis
Name Name Person Filing Proxy Statement Other Registrant
Nasdaq Shareholder Approval Requirements National Cancer Institute Not Precluded Working Other Companies
Need-to-know Negatively Impacted Application Enforcement Federal State Fraud Abuse
Net Loss Per Common Share Net Proceeds Private Placement Debentures
Net Sales Services Never Paid Dividends Common Stock Not Anticipate Paying
New Drug Application Nda Biologics License Bla New Market Tax Credit Financing
New Market Tax Credits Financing New Markets Tax Credits
New York 10017 News Media Outlets
Next Page Signature Nmtc Covenants
Non-controlling Intereset Income Loss Non-controlling Interest Income Loss
Non-hodgkins Lymphoma Non-patent Marketing Exclusivities
Non-qualified Deferred Compensation Non-reliance Previously Issued Financial Statements Related Audit
Non-transferability Plan Awards Not Able Maintain Sufficient Product Liability Insurance Cover
Not Able Obtain Maintain Orphan Drug Exclusivity Biovaxid Not Able Prevent Parties Including Potential Competitors Developing
Not Future Obtain License Mayo Antifungals Other Amphotericin Not Future Obtain License Mayo Foundation Antifungals Other
Notes Notes Consolidated Financial Statements
Notes Payable Notes Payable Related Parties
Notes Payable Related Party Notes Payable Stockholders
Notice Notice Conversion
Notice Exchange Notice Exercise
Notices Now Therefore Agreed
Now Therefore Parties Agree Follows Definitions Number Common Shareholders
Obligations Owed Holder Debenture Subordinated Right Payment Accordance Obligations Securities Laws Insider Trading
Occasionally Become Subject Commercial Disputes Harm Business Distracting Officers
Offices Omnibus Amendment Waiver
Operating Leases Option Agreement
Option Exercises Stock Vested Option License Antifungals Chronic Sinusitis
Options Exercised Options Granted Last
Options Stock Appreciation Rights Oral Agreements Commitments Loan Money Extend Credit Forbear
Organization Original Issue Discount Secured Convertible Debenture
Orphan Drug Designation Exclusivity Other
Other Acquisition Other Agreements
Other Companies Other Disbursements
Other Discussed Annual Meeting Other Discussed Meeting
Other Events Other Financing Arrangements
Other Financing Transactions Other Information
Other Intangible Assets Other Loan-related Provisions
Other Matters Other Notes Payable
Other Receipts Other Receipts Includes Loans Insiders Sources Officer Owner
Other Regulation United States Other Related Party Transactions
Other Transactions Outlook 2006
Overadvance Side-letter Overview
Ownership Common Stock Continues Highly Concentrated Prevent Other Pain Products
Part Part Ii- Other Information
Part Ii-other Information Party Rights
Patent Prosecution Enforcement Infringement Patent Term Restoration
Patents Applications Patents Issued
Patents Licenses Patents Patent Applications
Patents Trademark Patient Program Anti-cancer Vaccine Europe
Patients Maintain Complete Remissions Payment Plan Awards Conditions Thereon
Payments Gifts Others Pays Prepare Mail Solicit Proxies
Pending Milestones Biovaxid 2008 Pending Milestones Revimmune 2008
Pending Milestones Sinunase 2008 Pension Benefits
Performance Graph Period 2008 Through
Personnel Report Petty Cash Report
Pharmaceutical Product Consulting Services Pharmaceutical Product Regulation
Pharmacy Compounding Phase Safety Tolerability Study Johns Hopkins University
Phase Study Sinunase Treatment Chronic Sinusitis Phase Study Suny Stonybrook
Physicians Reluctant Prescribe Amphotericin Treatment Crs While Unapproved Piggyback Registration Rights
Pivotal Phase Clinical Trial Sinunase Chronic Sinusitis Pivotal Phase Results Sinunase
Plan Distribution Pledge Agreement
Pledged Shares Pledged Stock
Policy Audit Committee Pre-approval Permissible Non-audit Services Independent Political Contributions
Post Petition Accounts Receivable Aging Post-approval Phase
Post-petition Accounts Payable Potential Blockbusters Sinunase Biovaxid
Potential Profit Conversion Convertible Debentures Preferred Stock
Prepayment Prescription Drug Wrap-up Desi Products
Prescription Intranasal Formulations Symptoms Associated Chronic Sinusitis Pricing Payment Terms
Primary Endpoint Clinical Study Sinunase Lavage Principal Accountant Fees Services
Principal Accountants Fees Services Principal Amounts Due Creditors Listed Above
Principles Consolidation Private Placement
Private Placement Convertible Debentures Private Placements Capital Stock
Pro Forma Financial Information Procedure Submitting Shareholder Proposals
Procedures Reporting Violations Ensuring Compliance Code Proceeds
Proceeds Financing Product Development Agreement
Product Development Pipeline Product Liability
Product Manufacturing Supply Agreements Product Rights Obligations
Products Products Ndc Codes
Prohibition Against Short Selling Stock Promissory
Properties Property
Proposal 1-election Directors Proposal 2-ratification Independent Public Accountants
Proprietary Rights Proprietary Rights Biovaxid
Proprietary Rights Not Adequately Protect Technologies Product Candidates Proprietary Rights Sinunase
Publications Others Pulaski Bank Trust
Purchase Agreement Purchase Option Agreement
Purchase Price Payment Purchase Sale
Purchase Sale Assets Purchase Sale Equipment
Purchased In-process Research Development Purpose Amendment
Purpose Definitions Put Option Agreement
Qlici Loan Agreement Qualitative Quantitative Disclosures Market Risk
Quantitative Qualitative Disclosure Market Risk Quarterly Financial Data
Quarterly Results Fluctuate Questionnaire
Rate Interest Reaffirmation Guaranty
Reaffirmation Ratification Agreement Receive Fast Track Status Fda
Receiving Materials Recent Accounting Pronouncements
Recent Highlights Recent Sales Unregistered Securities
Recitals Recitals Definitions
Reclassification Reclassification Financial Instruments
Recommendation Board Directors Reducing Disability Improving Functions
References Registrants Telephone Number Including Area Code 508 793-0001
Registrants Telephone Number Including Area Code 813 864-2554 Registration Rights
Registration Rights Agreement Regulation Disclosure
Related Party License Agreement Sale Royalty Rights Related Party Sublicense Agreement
Related Party Transactions Related-party Transactions
Relationship Biodelivery Sciences International Inc Relationship Biodelivery Sciences Several Senior Executive Officers Creates
Relationship Biovest International Inc Relationship Mckesson Corporation
Relationship Pharmaceutical Product Development Inc Relationships
Release Claims Release Escrow
Remainder Page Been Left Intentionally Blank Remainder Page Intentionally Blank
Remainder Page Intentionally Blank Signature Follows Remainder Page Intentionally Left Blank
Remainder Page Intentionally Left Blank Signature Follows Remainder Page Left Blank Intentionally
Repayment Loan Amounts Report Audit Committee
Report Compensation Committee Report Independent Registered Certified Public Accounting Firm
Report Independent Registered Public Accounting Firm Representations Autovaxid
Representations Warranties Representations Warranties Buyer
Representations Warranties Lender Representations Warranties Responsibilities Parties
Representations Warranties Seller Required Vote
Research Development Research Development Expense
Reset Debenture Conversion Price Warrant Exercise Resolution Symptoms Reduction Polyps
Restatement Portions Previously-filed Financial Statements Restricted Account
Restricted Account Agreement Restricted Cash
Restrictions Transfer Exercise Option Restructure Intercompany Agreements Biovest
Revenue Recognition Revenues Receive Sublicensing Amphotericin Therapy Compounding Pharmacies Materially
Revenues Receive Sublicensing Amphotericin Therapy Crs Compounding Pharmacies Revimmune
Revimmune Agreements Revimmune Llc
Revolving Credit Revolving Credit Agreement
Revolving Credit Modification Agreement Rights Stockholder
Risk Factors Royalty Liability
Royalty Other Payments Reports Royalty Payments Reports
Sale Equipment Sales Marketing
Sales Marketing Manufacturing Sarikianbiovestcom
Sbonitzaccentianet Sbreweraccentianet
Schedule Schedule Biovest Trademark Oppositions
Schedule Capitalization Schedule Certain Fees
Schedule Liens Schedule Litigations
Schedule Noncompliant Fda Products Schedule Pledge Agreement
Schedule Registration Rights Agreement Schedule Seniority
Schedule Undisclosed Events Schedules
Sclerosis Seal
Secured Convertible Minimum Borrowing Secured Payments Report
Secured Promissory Securities Exchange Act 1934
Securities Purchase Agreement Security Agreement
Security Interest Granted Accentia Security Interest Granted Subsidiaries
Security Interests Granted Accentia Security Interests Granted Subsidiaries
Security Interests Liens Previously Granted Security Ownership Certain Beneficial Owners Management
See Graph Showing Disease-free Survival Curves Below See Separate Register
Segment Reporting Selecting Suppliers
Seller Disclosure Schedule Selling Securityholder Notice Questionnaire
Selling Stockholder Notice Questionnaire Seniority
Sent Via Electronic Delivery Apearceaccentianet Ssduffeyaolcom Series A-1 Convertible Preferred Stock
Services Settlement Agreement
Severance Claim Share-based Compensation
Shared Support Services Shipping Handling Costs
Signature Signature Page Follows
Signature Page Immediately Follows Signature Pages Follow
Signatures Signatures Appear Following Page
Signatures Following Page Significant Developments Reporting Period
Significant Portion Total Outstanding Shares Restricted Immediate Resale Sinunase
Sinunase Agreements Sinunase Fast-tracked Pivotal Phase Study Chronic Sinusitis Shows
Sixth Amendment Distribution Agreement Some Minority Stockholders Biovest Subsidiary Indicated They Believe
Some Provisions Amended Restated Articles Incorporation Bylaws Florida Some Specialty Pharmaceutical Products Not Subject Fda-approved New
Sources Liquidity Southwest Bank Creve Coeur Financial Center
Southwest Bank Louis Special Meeting Shareholders
Specialty Pharmaceutical Products Specialty Pharmaceuticals
Stanford State Other Jurisdiction Incorporation
Stock Available Plan Awards Stock Based Compensation
Stock Issuances Stock Options Warrants
Stock Other Stock-based Combination Awards Stock Pledged Odonnell Entities
Stock Price Volatile Investment Decline Value Stock Subject Plan Maximum Number Shares Common Respect
Stock-based Compensation Stockholder
Stockholder Advances Notes Stockholder Payable
Stockholders Deficit Stockholders Equity
Sublease Submission Matters Vote Security Holders
Subordinated Convertible Promissory Subordinated Promissory
Subordination Subordination Agreement
Subscription Agreement Subsequent Events
Subsidiaries Subsidiaries Shall Mean
Subsidiary Guarantee Sued Infringing Intellectual Property Rights Parties Such Litigation
Summary Compensation Table Summary Personnel Insurance Coverages
Support Accelerated Drug Commercialization Strategies Systemic Lupus
Tax Credit Reimbursement Indemnity Agreement Taxation Allocations Distributions
Taxes Owed Due Teamm Letterhead
Teamm Trademark Impairment Term
Term Amendment Modification Termination Plan Agreements Term Termination
Termination Termination Biologic Products Commercialization Agreement
Termination Material Definitive Agreement Termination Right Refusal Agreement
Terms Financing Third-party Reimbursement Pricing Controls
Title Class Total Shares Biovest Stock Held Transferable Debentures Warrants
Trade Stock Ddn 2006 Trademark Applications
Trademark Assignment Trademark Registrations
Trademarks Transfers Between Debtor Possession Accounts
Treasury Department Treatment Chronic Sinusitis
Treatment Refractory Chronic Sinusitis Turbo
Turbo Impairment Unbilled Receivables Unearned Revenues
Unfulfilled Registration Rights Agreements Unfunded Status Plan
Unique Approach Immunotherapy Targeting B-cell Blood Cancers Unless Extended Pursuant Hereof
Unregistered Sales Equity Securities Unregistered Sales Equity Securities Proceeds
Update Usb Means Bancorp Community Investment Corporation Other Definitional
Valens Offshore Spv Corp Valens Offshore Spv Corp Llc Secured Promissory Notes
Valens Offshore Spv Corp Ltd Llc Secured Promissory Valens Spv Llc
Valuation Derivative Instruments Valuation Goodwill Intangible Assets
Variable Interest Entities Variable Interest Entity
Vendors Specialty Pharmaceuticals Segment Provided Approximately Total Product Venue Such Courts Parties Agree Service Process Them
Victory Vote
Vote Directors Votes Counted
Vwr International Inc Vwr Marketing Plan
Waiver Conditions Exhibits Waiver Jury Trial
Waivers Warrant
Warrant Purchase Agreement Warrants Issued Related Parties
Warrants Issued Related Parties Guarantees Debt What Boards Recommendations
What Constitutes Quorum What Effect Not Voting
What Vote Required Approve Proposals What Voting
Whereas Acheron Accentia Teamm Mutually Agreed Terminate Distribution Whereas Argent Accentia Teamm Agreed Delete 200 Product
Whereas Argent Accentia Teamm Agreed Delete 300 Product Whereas Ryan Accentia Teamm Mutually Agreed Delete 300
Wholly-owned Subsidiaries Wire Instructions
Wire Transfer Instructions Witness Whereof Fifth Amendment Distribution Agreement Been Duly
Witness Whereof Mutual Termination Agreement Been Duly Executed Witness Whereof Sixth Amendment Distribution Agreement Been Duly
Witnesset Witnesseth
Workplace Safety Security 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki